|
Sustained growth in the third quarter of 2013
2013.11.14
|
|---|
|
Sustained Growth in the Third Quarter of 2013
- Sales up 18.3% and operating profit up 27.8% year-on-year - Continuous quarterly improvement, with Q3 sales up 12.7% and operating profit up 27.0% compared to the previous quarter - Brand marketing efforts strengthening market recognition
Daehan New Pharm’s growth continued into the third quarter of 2013.
Despite a challenging business environment marked by stringent regulations and intense competition, the company’s pharmaceutical division has steadily improved both growth and profitability month by month. Through quality-focused, profit- and collection-centered management, the company achieved solid growth of around 20%, while enhanced internal financing capacity contributed to greater financial stability.
In the third quarter, Daehan New Pharm recorded cumulative sales of 41.74 billion KRW, up 18.3% year-on-year, and operating profit of 4.09 billion KRW, a 27.8% increase. Ordinary profit turned to a surplus of 1.31 billion KRW from a 706 million KRW loss in the same period last year. Since the third quarter of 2011, the company has posted steady quarter-to-quarter growth, with Q3 2013 sales rising 12.7% and operating profit jumping 27.0% compared to the previous year’s same period.
The company is also strengthening its market presence through various seminars and co-creation research activities with key doctors on differentiated wellness and beauty solutions, building stronger relationships with medical professionals and enhancing brand image. Customer response to its wellness beauty solution products, Luthione Injection and Cindella Injection, remains strong, while tangible results from its “Customer Value–Centered Sales Innovation Program” are becoming evident.
This upward performance trend is expected to continue through the fourth quarter and beyond, providing a solid foundation for Daehan New Pharm to advance as a leading small but strong enterprise. |


Home